NurExone Biologic Inc., a biopharmaceutical company developing biologically-guided exosome therapy, for patients with traumatic spinal cord injuries, is pleased to announce the interim results of an internal, preclinical study of its ExoPTEN drug.
TORONTO and HAIFA, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”), for patients with traumatic spinal cord injuries, is pleased to announce the interim results of an internal, preclinical study of its ExoPTEN drug. ExoPTEN is being developed by NurExone as a minimally invasive drug, aimed at capitalizing on the $2.9 billion market for acute Spinal Cord Injuries (SCI) (https://www.reportlinker.com/p05960165/Global-Spinal-Cord-Trauma-Treatment-Industry.html?utm_source=GNW).
The current study was designed to assess the impact of ExoPTEN on the motor, reflex, and sensory recovery of rats, following full transection (i.e. complete severing) of the spinal cord. The interim results, four weeks post-transection, showed that:
- In the ExoPTEN treated group comprising four rats that received intranasal administration of ExoPTEN, 75% of the rats responded to treatment and recovered hind limb reflex, rehabilitated some motor function, and recovered sensory control. (Figs 1-3)
- In the exosome only treated group and in the therapeutic PTEN siRNA molecule only treated group, comprising four rats each, 25% of the rats responded to treatment and recovered hind limb reflex, motor function, and recovered sensory control. (Figs 1-2)
- In a control group, comprising six rats that received a (non-therapeutic) saline solution, none of the rats demonstrated any sensory or reflex recovery or motor rehabilitation. (Figs 1-3)
“The interim results of the study strongly suggest that ExoPTEN yields partial rewiring of the spinal cord in rats, bringing recovered capability,” commented Dr. Lior Shaltiel, CEO of NurExone. “We are committed to bringing effective ExoTherapy-based products from the lab to patients who can benefit from them.”
ExoPTEN is based on the company’s proprietary ExoTherapy platform, in which exosomes are produced and loaded with therapeutic molecules for delivery to damaged cells in the body. The current study assessed ExoPTEN with an improved and modified siRNA (small interfering RNA) sequence as its therapeutic cargo. ExoPTEN, as an ExoTherapy-based drug, is designed to promote neuron regeneration and rewiring in traumatically damaged spinal cords, while being an “off-the-shelf” drug with minimally invasive administration.
The interim results will be presented at the ILANIT Experimental Biology Conference 2023 by NurExone’s Director of R&D, Dr. Lyora Aharonov on Tuesday, February 21 at 10:15 AM (Israel Standard Time). The title of Dr. Aharonov’s presentation is “Exosome-based therapy for spinal cord injury - a holistic approach.”
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSX Venture Exchange listed pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries. ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. NurExone is translating the treatment to humans, and the company holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology.
For more information on NurExone Biologic Inc., ExoPTEN and the ExoTherapy platform, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
Investor Relations (Canada)
Phone: +1 905-347-5569
Email: IR@nurexone.com
FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. When used in this press release, forward-looking statements can be identified by the use of words such as “may,” or by such words as “will,” “intend,” “believe,” “estimate,” “consider,” “expect,” “anticipate,” and “objective” and similar expressions or variations of such words. Forward-looking statements are, by their nature, not guarantees of the Company’s future operational or financial performance and are subject to risks and uncertainties and other factors that could cause the Company’s actual results, performance, prospects, or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. No representation or warranty is intended with respect to anticipated future results, or that estimates, or projections will be sustained.
Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions, and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this press release include, but are not limited to, statements relating to: our future plans and intellectual property; our scientific and development activities; future scientific activities and the treatment of certain conditions; the therapeutic benefits, effectiveness, and safety of our product candidates; and the estimated growth of the market for acute Spinal Cord Injuries.
In developing the forward-looking statements in this press release, we have applied several material assumptions, including that the interim results are indicative of results that may be seen in future studies, third party sources of industry data represent reasonable estimates, our ability to retain key personnel, our ability to continue investing in research and development, our ability to secure available funding and to continue as a going concern; the general business and economic conditions of the industries and countries in which we operate; and our ability to execute on our business strategy.
Many risks, uncertainties, and other factors could cause the actual results of the Company to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the following: those risk factors identified under the heading “Risk Factors” on pages 62 to 69 of the Company’s Filing Statement dated May 12, 2022, a copy of which is available under the Company’s SEDAR profile at www.sedar.com; risks related to the Company’s early stage of development; lack of revenues to date; government regulation; market acceptance for our products; rapid technological change; dependence on key personnel; protection of our intellectual property; dependence on our strategic partners; overall economic conditions; competitive pressures; network restrictions; and other similar factors that may cause the actual results, performance or achievements to differ materially from those expressed or implied in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of the press release or as of the date otherwise specifically indicated herein. Due to risks and uncertainties, events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required pursuant to applicable securities law. All forward-looking statements contained in the press release are expressly qualified in their entirety by this cautionary statement.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Photo accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/1ccd5dc4-7ffe-4e21-a143-a3389cfcaad5
https://www.globenewswire.com/NewsRoom/AttachmentNg/68770707-6154-47f9-98e5-388219c3a709
https://www.globenewswire.com/NewsRoom/AttachmentNg/04faafb4-7562-4240-891f-6a11d0d6cc1e
PR Scientific 160223 Figure 1
Figure 1
PR Scientific 160223 Figure 2
Figure 2
PR Scientific 160223 Figure 3
